249 related articles for article (PubMed ID: 30142705)
1. Amyloid oligomerization of the Parkinson's disease related protein α-synuclein impacts on its curvature-membrane sensitivity.
Gallea JI; Ambroggio EE; Vilcaes AA; James NG; Jameson DM; Celej MS
J Neurochem; 2018 Nov; 147(4):541-556. PubMed ID: 30142705
[TBL] [Abstract][Full Text] [Related]
2. α-synuclein-assisted oligomerization of β-amyloid (1-42).
Chau E; Kim JR
Arch Biochem Biophys; 2022 Mar; 717():109120. PubMed ID: 35041853
[TBL] [Abstract][Full Text] [Related]
3. Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).
Follmer C; Coelho-Cerqueira E; Yatabe-Franco DY; Araujo GD; Pinheiro AS; Domont GB; Eliezer D
J Biol Chem; 2015 Nov; 290(46):27660-79. PubMed ID: 26381411
[TBL] [Abstract][Full Text] [Related]
4. Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.
Coskuner-Weber O; Uversky VN
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364151
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Amyloid Switch Triggered by Early Heterotypic Oligomerization of Intrinsically Disordered α-Synuclein and Tau.
Bhasne K; Sebastian S; Jain N; Mukhopadhyay S
J Mol Biol; 2018 Aug; 430(16):2508-2520. PubMed ID: 29704492
[TBL] [Abstract][Full Text] [Related]
6. Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases.
Choi ML; Gandhi S
FEBS J; 2018 Oct; 285(19):3631-3644. PubMed ID: 29924502
[TBL] [Abstract][Full Text] [Related]
7. Effects of phosphatidylcholine membrane fluidity on the conformation and aggregation of N-terminally acetylated α-synuclein.
O'Leary EI; Jiang Z; Strub MP; Lee JC
J Biol Chem; 2018 Jul; 293(28):11195-11205. PubMed ID: 29853639
[TBL] [Abstract][Full Text] [Related]
8. Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease.
van Rooijen BD; Claessens MM; Subramaniam V
Curr Protein Pept Sci; 2010 Aug; 11(5):334-42. PubMed ID: 20423294
[TBL] [Abstract][Full Text] [Related]
9. Heme Stabilization of α-Synuclein Oligomers during Amyloid Fibril Formation.
Hayden EY; Kaur P; Williams TL; Matsui H; Yeh SR; Rousseau DL
Biochemistry; 2015 Aug; 54(30):4599-610. PubMed ID: 26161848
[TBL] [Abstract][Full Text] [Related]
10. α-synuclein oligomers enhance astrocyte-induced synapse formation through TGF-β1 signaling in a Parkinson's disease model.
Diniz LP; Matias I; Araujo APB; Garcia MN; Barros-Aragão FGQ; Alves-Leon SV; de Souza JM; Foguel D; Figueiredo CP; Braga C; Romão L; Gomes FCA
J Neurochem; 2019 Jul; 150(2):138-157. PubMed ID: 31009074
[TBL] [Abstract][Full Text] [Related]
11. Two different binding modes of α-synuclein to lipid vesicles depending on its aggregation state.
Högen T; Levin J; Schmidt F; Caruana M; Vassallo N; Kretzschmar H; Bötzel K; Kamp F; Giese A
Biophys J; 2012 Apr; 102(7):1646-55. PubMed ID: 22500765
[TBL] [Abstract][Full Text] [Related]
12. Lipid vesicles affect the aggregation of 4-hydroxy-2-nonenal-modified α-synuclein oligomers.
Sardar Sinha M; Villamil Giraldo AM; Öllinger K; Hallbeck M; Civitelli L
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3060-3068. PubMed ID: 29960040
[TBL] [Abstract][Full Text] [Related]
13. The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson's Disease.
Galvagnion C
J Parkinsons Dis; 2017; 7(3):433-450. PubMed ID: 28671142
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane.
Beyer K
Cell Biochem Biophys; 2007; 47(2):285-99. PubMed ID: 17652776
[TBL] [Abstract][Full Text] [Related]
15. Membrane Interactions of α-Synuclein Probed by Neutrons and Photons.
Kaur U; Lee JC
Acc Chem Res; 2021 Jan; 54(2):302-310. PubMed ID: 33415971
[TBL] [Abstract][Full Text] [Related]
16. Nitroalkylation of α-Synuclein by Nitro-Oleic Acid: Implications for Parkinson's Disease.
Chavarría C; Trostchansky A; Durán R; Rubbo H; Souza JM
Adv Exp Med Biol; 2019; 1127():169-179. PubMed ID: 31140178
[TBL] [Abstract][Full Text] [Related]
17. Amyloid fibrils act as a reservoir of soluble oligomers, the main culprits in protein deposition diseases.
Bigi A; Cascella R; Chiti F; Cecchi C
Bioessays; 2022 Nov; 44(11):e2200086. PubMed ID: 36104212
[TBL] [Abstract][Full Text] [Related]
18. Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases.
Forloni G; Artuso V; La Vitola P; Balducci C
Mov Disord; 2016 Jun; 31(6):771-81. PubMed ID: 27030592
[TBL] [Abstract][Full Text] [Related]
19. Structural remodeling during amyloidogenesis of physiological Nα-acetylated α-synuclein.
Gallea JI; Sarroukh R; Yunes-Quartino P; Ruysschaert JM; Raussens V; Celej MS
Biochim Biophys Acta; 2016 May; 1864(5):501-10. PubMed ID: 26845568
[TBL] [Abstract][Full Text] [Related]
20. Structural and mechanistic insights into amyloid-β and α-synuclein fibril formation and polyphenol inhibitor efficacy in phospholipid bilayers.
Sanders HM; Jovcevski B; Marty MT; Pukala TL
FEBS J; 2022 Jan; 289(1):215-230. PubMed ID: 34268903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
